Design and development of a commercially viable in situ nanoemulgel for the treatment of postmenopausal osteoporosis
Abstract
Aim: To investigate the potential of a thermosensitive intranasal formulation of raloxifene hydrochloride (RH) for systemic delivery with the possibility of enhanced bioavailability and anti-osteoporotic efficacy. Methods: In this work, a commercially scalable nanoemulsion in thermosensitive gel, aligned with better clinical acceptability, has been developed and evaluated. Results: A significant 7.4-fold improvement in bioavailability of RH was recorded when compared with marketed tablets. Likewise, in vivo pharmacodynamics studies suggested 162% enhanced bone density and significantly improved biochemical markers compared with per-oral marketed tablet. Conclusion: The formulation, being safe and patient compliant, successfully tuned anti-osteoporotic effects with improved therapeutic performance. Further, the work provided an exceptional lead to carry out the study in clinical settings.
Graphical abstract
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. International Osteoporosis Foundation. The Asian Audit: epidemiology, costs and burden of osteoporosis in Asia. www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/Asian_regional_audit_2009.pdf
- 2. . Review of drugs approved via the 505(b)(2) pathway: uncovering drug development trends and regulatory requirements. Ther. Innov. Regul. Sci. 7, 1–11 (2019). •• Highlights the use of a new dosage form for a previously approved drug product and the regulatory requirements for the fulfillment of 505(b)(2) pathway.
- 3. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282(7), 637–645 (1990).
- 4. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr. Med. Res. Opin. 28(3), 475–491 (2012).
- 5. . Enhanced dissolution and bioavailability of raloxifene hydrochloride by co-grinding with different superdisintegrants. Chem. Pharm. Bull. (Tokyo) 58(3), 293–300 (2010). • The differential scanning calorimetry and x-ray diffraction techniques assess the crystalline nature of the drug molecule which serves as a proof for enhanced aqueous solubility.
- 6. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos. Int. 27(3), 1227–1238 (2016).
- 7. . Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery. Expert Opin. Drug Deliv. 10(1), 115–130 (2013).
- 8. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics 10(1), 1–34 (2018).
- 9. Nanoemulsion for solubilization, stabilization and in vitro release of pterostilbene for oral delivery. AAPS PharmSciTech 5(4), 1000–1008 (2014).
- 10. Carbopol-incorporated thermoreversible gel for intranasal drug delivery. Molecules 20(3), 4124–4135 (2015). • A combination of poloxamer and carbopol has good thermogelling and mucoadhesive properties. The polymers are used for the formulation of an in situ gel for nasal application.
- 11. . Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 23(3), 681–693 (2016).
- 12. . Development of in situ poloxamer-chitosan hydrogels for vaginal drug delivery of benzydamine hydrochloride: textural, mucoadhesive and in vitro release properties. Marmara. Pharm. J. 21(4), 762–770 (2017).
- 13. . Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv. Drug Deliv. Rev. 92, 39–52 (2015).
- 14. . Design and characterization of nanoemulsion for transdermal delivery of meloxicam. Anal. Chem. Lett. 6(3), 286–295 (2016).
- 15. . Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. Artif. Cells Nanomed. Biotechnol. 43(5), 334–344 (2015).
- 16. . Formulation and evaluation of norcanthridin nanoemulsions against the Plutella xylostella (Lepidotera: plutellidae). BMC Biotechnol. 19(1), 1–11 (2019).
- 17. . Enhancement of solubility and dissolution rate of poorly water soluble raloxifene using microwave induced fusion method. Braz. J. Pharm. Sci. 49(3), 571–578
- 18. Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride. J. Pharm. Sci. 100(2), 681–691 (2011).
- 19. . Rheological, mucoadhesive and release properties of pluronic F-127 gel and pluronic F-127/polycarbophil mixed gel systems. Pharmazie 60(7), 518–523 (2005).
- 20. Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. Int. J. Pharm. 430(1–2), 114–118 (2012).
- 21. Effect of sodium chloride on gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int. J. Pharm. 226(1–2), 195–205 (2001).
- 22. . Rheological and mechanical properties of poloxamer mixtures as a mucoadhesive gel base. Pharm. Dev. Technol. 16(6), 627–636 (2011).
- 23. . Examination of the flow rheological and textural properties of polymer gels composed of poly(methylvinyletherco-maleic anhydride) and poly(vinylpyrrolidone): rheological and mathematical interpretation of textural parameters. J. Pharm. Sci. 91, 2090–2101 (2002).
- 24. . Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J. Drug Target. 18(3), 223–234 (2010).
- 25. . Design and development of letrozole nanoemulsion: a comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice. Int. J. Pharm. 565, 20–32 (2019).
- 26. . Enhanced nasal drug delivery efficiency by increasing mechanical loading using hypergravity. Sci. Rep. 8(1), 168 (2018).
- 27. . Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 855, 220–227 (2007).
- 28. . Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. Bio. Med. Res. Int. 2013, 584–549 (2013).
- 29. . Description of a new method of ovariectomy in female rats. Rev. Bras. Reumatol. 52(3), 462–470 (2012). • Ovariectomy is a successful method for onset of osteoporosis.
- 30. 3-Piperidylethoxypterocarpan: a potential bone anabolic agent that improves bone quality and restores trabecular micro-architecture in ovariectomized osteopenic rats. Mol. Cell. Endocrinol. 448, 41–54 (2017).
- 31. . Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-κB signaling pathway in rats. Exp. Ther. Med. 14(5), 5032–5038 (2017).
- 32. . Postmenopausal women with osteoarthritis and osteoporosis show different ultrastructural characteristics of trabecular bone of the femoral head. BMC Musculoskelet. Disord. 10, 35 (2009).
- 33. . Ca/P concentration ratio at different sites of normal and osteoporotic rabbit bones evaluated by Auger and energy dispersive x-ray spectroscopy. J. Biol. Phys. 38(2), 279–291 (2012).
- 34. . Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. Pharm. Dev.Technol. 20(8), 992–1001 (2015).
- 35. . Natural surfactants-based micro/nanoemulsion systems for NSAIDs – practical formulation approach, physicochemical and biopharmaceutical characteristics/performances. In: Microsized and Nanosized Carriers for Nonsteroidal Anti-inflammatory Drugs, Formulation Challenges and Potential Benefits, 1st Edition. Calija B (Ed.). Academic Press, NY, USA, 179–217 (2017).
- 36. . Effect of surfactant and oil type on size droplets of betacarotene-bearing nanoemulsions. Int. J. Curr. Microbiol. App. Sci. 4(9), 146–155 (2015).
- 37. . Temperature profile in the nasal cavity. Laryngoscope 110(4), 651–654 (2000).
- 38. . Formation of food-grade nanoemulsions using low-energy preparation methods: a review of available methods. Compr. Rev. Food Sci. Food Saf. 15(2), 331–352 (2016).
- 39. . The effect of surfactant on the physical properties of coconut oil nanoemulsions. Asian J. Pharm. Sci. 13(5), 409–414 (2018).
- 40. . Optimization of quercetin loaded palm oil ester based nanoemulsion formulation for pulmonary delivery. J. Oleo. Sci. 67(8), 933–940 (2018).
- 41. . Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm. 66(2), 227–243 (2007). •• Oil-in-water nanoemulsion improves the hydrophilicity of lipophilic drugs.
- 42. . Optimization of orange oil nanoemulsion formation by isothermal low-energy methods: influence of the oil phase, surfactant, and temperature. J. Agric. Food Chem. 62(10), 2306–2312 (2014).
- 43. Enrichment of Eucalyptus oil nanoemulsion by micellar nanotechnology: transdermal analgesic activity using hot plate test in rats assay. Sci. Rep. 9(1), 13678 (2019). •• The presence of micelles in the nanoemulsion system destabilizes the formulation. A minimum amount is necessary to improve the stability of the delivery system.
- 44. . Production and characterization of cosmetic nanoemulsions containing Opuntia ficus-indica (L.) Mill extract as moisturizing agent. Molecules 20(2), 2492–2509 (2015).
- 45. . Electron microscopy of nanoemulsions: an essential tool for characterisation and stability assessment. Micron 43(2-3), 85–103 (2012).
- 46. . Crystalline and amorphous carvedilol-loaded nanoemulsions: formulation optimisation using response surface methodology. J. Exp. Nanosci. 8(7–8), 971–992 (2012).
- 47. . Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1), 89–121 (2000).
- 48. . Stable drug encapsulation in micelles and microemulsions. Int. J. Pharm. 345(1–2), 9–25 (2007).
- 49. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 452(1-2), 412–420 (2013).
- 50. . Effect of HPMC and mannitol on drug release and bioadhesion behavior of buccal discs of buspirone hydrochloride: in-vitro and in-vivo pharmacokinetic studies. Saudi Pharm. J. 23(3), 315–326 (2015).
- 51. . Characterization of D-mannitol by thermal analysis, FTIR, and Raman Spectroscopy. Am. Lab. 40(14), 24–27 (2008).
- 52. . Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Drug Deliv. 15(5), 313–321 (2008).
- 53. . Intranasally administered in situ gelling nanocomposite system of dimenhydrinate: preparation, characterization and pharmacodynamic applicability in chemotherapy induced emesis model. Sci Rep. 7(1), 9910 (2017). • Poloxamer 407 has been used for formulating thermosensitive in situ gels for intranasal delivery. The gel showed biocompatibility with the nasal tissue.
- 54. . In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin . Eur. J. Pharm. Biopharm. 122, 54–61 (2018).
- 55. Comparison of poloxamer- and chitosan-based thermally sensitive gels for the treatment of vaginal mucositis. Drug Dev. Ind. Pharm. 40(3), 352–360 (2014).
- 56. Poloxamer-based thermoreversible gel for topical delivery of Emodin: influence of P407 and P188 on solubility of Emodin and its application in cellular activity screening. Molecules 22(2), E246 (2017).
- 57. . Mucosal applications of poloxamer 407-based hydrogels: an overview. Pharmaceutics 10(3), E159 (2008).
- 58. . Study of the mucoadhesive potential of carbopol polymer in the preparation of microbeads containing the antidiabetic drug Glipizide. AAPS PharmSciTech. 17(3), 743–756 (2016).
- 59. . Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies. J. Liposome Res. 26(4), 313–323 (2016).
- 60. . Mucoadhesive and physicochemical characterization of carbopol-poloxamer gels containing triamcinolone acetonide. Drug Dev. Ind. Pharm. 26(3), 307–312 (2000).
- 61. . A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS ONE 12(12), e0189478 (2017).
- 62. . Bioadhesive microspheres for bioavailability enhancement of Raloxifene hydrochloride: formulation and pharmacokinetic evaluation. AAPS Pharm. Sci. Tech. 12(2), 650–657 (2011).
- 63. . A comparative in vitro release study of raloxifene encapsulated ordered MCM-41 and MCM-48 nanoparticles: a dissolution kinetics study in simulated and biorelevant media. J. Drug Deliv. Sci. Technol. 41, 31–44 (2017).
- 64. . In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance . Int. J. Nanomedicine 13, 6325–6335 (2018). •• Nasal delivery of Raloxifene hydrochloride improves the bioavailability. The combination of nanoemulsion and micelles provides enhanced absorption from the nasal mucosa to the systemic route.
- 65. . Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. Carbohydrates 99, 297–305 (2014).
- 66. In vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for nasal administration of dimenhydrinate . Drug Deliv. Transl. Res. 9(5), 945–955 (2019).
- 67. . Carbopol-based gels for nasal delivery of progesterone. AAPS PharmSciTech. 9(4), 1078–1082 (2008).
- 68. . Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr. Drug Deliv. 9, 566–582 (2012).
- 69. . Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech. 7(3), 67 (2006).
- 70. . Nasal drug delivery: new developments and strategies. Drug Discov. Today 7(23), 1184–1189 (2002).
- 71. . Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. Ther. Clin. Risk. Manag. 13, 1343–1348 (2017).
- 72. . Serum osteocalcin as a diagnostic biomarker for primary osteoporosis in women. J. Clin. Diagn. Res. 9(8), RC04–RC07 (2015).
- 73. . Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal osteoporosis. Calcif. Tissue Int. 45(1), 58–60 (1989).
- 74. . Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark. Res. 5, 18 (2017). • The bone markers help in clinical assessment of osteoporosis. The functions of alkaline phosphatase, osteocalcin, estrogen and creatinine in the bone remodeling process was elaborated.
- 75. . Lower serum creatinine is associated with low bone mineral density in subjects without overt nephropathy. PLoS ONE 10(7), e0133062 (2015).
- 76. . The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106(10), 1203–1204 (2000).
- 77. . Energy dispersive x-ray (EDX) microanalysis: a powerful tool in biomedical research and diagnosis. Eur. J. Histochem. 62(1), 2841 (2018).
- 78. . An evidence-based review of micro-CT assessments of the postmenopausal osteoporosis rat model. Int. J. Pharmacology. 11(3), 177–200 (2015).
- 79. . Using micro-CT derived bone microarchitecture to analyze bone stiffness – a case study on osteoporosis rat bone. Front. Endocrinol. (Lausanne) 6, 80 (2015).